TG Therapeutics, Inc.
TGTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4 | $2 | $2 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $4 | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 40.8% | 8,290% | -58.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 88.3% | 94% | 90.5% | 88.2% |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 15.2% | 11.2% | -7,651.9% | -5,112.4% |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 7.1% | 5.4% | -8,036.3% | -5,204.1% |
| EPS Diluted | 0.15 | 0.085 | -1.46 | -2.63 |
| % Growth | 75.8% | 105.8% | 44.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |